Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol

Author： Sasaki H. Hashimoto K. Inada T. Fukui S. Iyo M.

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.282, Iss.1, 1995-08, pp. : 71-76

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram

By Iyo M. Ying B. Hashimoto K. Inada T. Fukui S.

European Journal of Pharmacology, Vol. 312, Iss. 2, 1996-09 ,pp. : 163-170

Elsevier

Access to resources Recommend Favorite

Cilostazol, a selective cAMP phosphodiesterase inhibitor, dilates retinal arterioles and increases retinal and choroidal blood flow in rats

By Hotta H. Ito H. Kagitani F. Sato A.

European Journal of Pharmacology, Vol. 344, Iss. 1, 1998-02 ,pp. : 49-52

Elsevier

Access to resources Recommend Favorite

Phosphodiesterase type 4 that regulates cAMP level in cortical neurons shows high sensitivity to rolipram

By Yamashita N. Yamauchi M. Baba J. Sawa A.

European Journal of Pharmacology, Vol. 337, Iss. 1, 1997-10 ,pp. : 95-102

Elsevier

Access to resources Recommend Favorite

Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor- synthesis

By Greten T.F. Sinha B. Haslberger C. Eigler A. Endres S.

European Journal of Pharmacology, Vol. 299, Iss. 1, 1996-03 ,pp. : 229-233

Elsevier

Access to resources Recommend Favorite

Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil

By Kato H. Araki T. Itoyama Y. Kogure K.

European Journal of Pharmacology, Vol. 272, Iss. 1, 1995-01 ,pp. : 107-110

Elsevier

Access to resources Recommend Favorite